RT Journal Article
SR Electronic
A1 Powers, Jenny
T1 Long-Term Adalimumab is Safe and Achieves Disease Control in Children with Advanced and Refractory JIA
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 17
SP 13
OP 14
DO 10.1177/155989771417004
UL http://mdc.sagepub.com/content/14/17/13.abstract
AB Long-term disease control was observed with adalimumab administered in routine clinical practice to patients with moderately to severely active juvenile idiopathic arthritis (JIA). This article discusses interim findings from an analysis done at 4 years from an ongoing international registry of patients enrolled upon diagnosis of moderately to severely active JIA [NCT00783510].